Plain-English translation of NCT07133880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether two different ways of delivering long-acting breathing medications work equally well for people with COPD. One group will use a dry powder inhaler (a device you breathe in from), while another group will use a nebulizer (a machine that turns liquid medication into a mist you inhale). Researchers want to understand if the delivery method affects how well the medication works.
People with COPD have different options for how to take their medications, but doctors don't have clear evidence about whether one delivery method is better than another. This study will help answer that question so patients and doctors can choose the method that works best.
You likely qualify if…
You likely don't qualify if…
You will attend several visits over 13 weeks. At your first visit, the study team will train you on how to use both an inhaler and a nebulizer, and you'll complete some questionnaires about your breathing and quality of life. At your second visit (about one week later), you'll have lung function testing and then be randomly assigned to receive your medications either through an inhaler or a nebulizer for the next 12 weeks. Throughout the study, you'll keep a daily diary of your symptoms and medications, complete follow-up visits to check your progress, and have repeat lung function tests at the end.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States